公开(公告)号：US20220356174A1

公开(公告)日：2022-11-10

申请号：US17262395

申请日：2019-07-24

申请人： Epizyme, Inc.

发明人： Oscar Moradei ,  John W. Lampe ,  Darren Martin Harvey ,  John Emmerson Campbell ,  Kenneth William Duncan ,  Michael John Munchhof

IPC分类号： C07D409/12 ,  A61P35/00 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D401/14 ,  C07D491/056 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D213/75 ,  C07D495/04 ,  C07D498/04

摘要： This disclosure generally relates to pyridine-2-one compounds of formula (I) and methods of using them in the treatment of a disorder, such as cancer or a SMARCA2-associated disorder, including as antagonists (e.g., inhibitors) of SMARCA2. The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, compounds, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancers. Some aspects of this disclosure provide treatment modalities, methods, strategies, compounds, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers with decreased activity or function, or loss of function, of SMARCA4 with a SMARCA2 antagonist.